Cempra Announces Proposed Public Offering of Common Stock
CHAPEL HILL, N.C., June 13, 2013
CHAPEL HILL, N.C., June 13, 2013 /PRNewswire/ --Cempra, Inc. (Nasdaq: CEMP),
a clinical-stage pharmaceutical company focused on developing differentiated
antibiotics to meet critical medical needs in the treatment of bacterial
infections, today announced its intention to offer and sell shares of its
common stock in an underwritten public offering pursuant to its existing shelf
registration statement. The company also intends to grant to the underwriters
a 30-day option to purchase up to an additional 15% of the shares of common
stock sold in the public offering to cover over-allotments, if any. The
company intends to use the net proceeds from the offering to fund its planned
IV-to-oral Phase 3 clinical trial of solithromycin in community acquired
bacterial pneumonia (CABP), working capital and general corporate and
administrative expenses. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the offering
may be completed, or as to the actual size or terms of the offering.
Barclays, Stifel and Cowen and Company are acting as joint book-running
managers for the offering.
The securities described above are being offered by Cempra pursuant to a
registration statement previously filed and declared effective by the
Securities and Exchange Commission. This press release does not constitute an
offer to sell or a solicitation of an offer to buy the securities in this
offering. The offering may be made only by means of a prospectus, copies of
which may be obtained, when available, from Barclays Capital Inc. by calling
1-888-603-5847, or by mail at Barclays Capital Inc. c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by e-mail at
Barclaysprospectus@broadridge.com; and from Stifel, Nicolaus & Company,
Incorporated by mail at One Montgomery Street, 36^th Fl., San Francisco, CA
94104, by telephone at 415-364-2720 or by e-mail at email@example.com.
About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company
focused on developing antibiotics to meet critical medical needs in the
treatment of bacterial infectious diseases. Cempra's two lead product
candidates are currently in advanced clinical development. Solithromycin
(CEM-101) is in a Phase 3 clinical trial for community-acquired bacterial
pneumonia (CABP) and is licensed to strategic commercial partner Toyama
Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain
exclusive rights in Japan. TAKSTA™ (CEM-102) is Cempra's second product
candidate currently in a Phase 2 clinical trial for prosthetic joint
infections. Both seek to address the need for new treatments targeting
drug-resistant bacterial infections in the hospital and in the community. The
company also intends to use its series of proprietary lead compounds from its
novel macrolide library for uses such as the treatment of chronic inflammatory
diseases, endocrine diseases and gastric motility disorders. Additional
information about Cempra can be found at www.cempra.com.
Please Note: This press release contains forward-looking statements regarding
future events. These statements are just predictions and are subject to risks
and uncertainties that could cause the actual events or results to differ
materially. These risks and uncertainties include, among others: risks
relating to the completion of the public offering, including the satisfaction
of customary closing conditions and the use of anticipated proceeds; the
results, timing, costs and regulatory review of our studies and clinical
trials; our need to obtain additional funding and our ability to obtain future
funding on acceptable terms; our anticipated capital expenditures and our
estimates regarding our capital requirements; the results of studies of our
product candidates conducted by others; the possible impairment of, or
inability to obtain, intellectual property rights and the costs of obtaining
such rights from third parties; our ability to obtain FDA approval of our
product candidates; our dependence on the success of solithromycin and Taksta;
and innovation by our competitors. The reader is referred to the documents
that we file from time to time with the Securities and Exchange Commission.
Robert E. Flamm, Ph.D.
Russo Partners, LLC
Russo Partners, LLC
Karine Kleinhaus, M.D.
Russo Partners, LLC
SOURCE Cempra, Inc.
Press spacebar to pause and continue. Press esc to stop.